<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684045</url>
  </required_header>
  <id_info>
    <org_study_id>P15-03</org_study_id>
    <nct_id>NCT02684045</nct_id>
  </id_info>
  <brief_title>Retrospective Chart Review to Assess Outcomes in Subjects That Received MAGNIFUSE® in the Posterolateral Lumbar Spine</brief_title>
  <official_title>A Retrospective Review of Charts to Assess Outcomes in Subjects That Received MAGNIFUSE® DBM in the Posterolateral Lumbar Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <brief_summary>
    <textblock>
      The purpose of this chart review is to assess outcomes in subjects that received MAGNIFUSE in&#xD;
      the posterolateral lumbar spine at 1 or 2 continuous levels from L1-S1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">August 15, 2017</completion_date>
  <primary_completion_date type="Actual">August 15, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion status at 12 or 24 months</measure>
    <time_frame>12 or 24 months</time_frame>
    <description>Fusion status will be assessed using the Lenke posterior fusion criteria below:&#xD;
Grade I: Solid trabeculated transverse process and facet fusions bilaterally.&#xD;
Grade II: Thick fusion mass on one side, and difficult to visualize on the other side.&#xD;
Grade III: Suspected lucency or defect in the fusion mass.&#xD;
Grade IV: Definite resorption of graft with fatigue of instrumentation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Back pain and leg pain measured by visual analog scale (VAS)</measure>
    <time_frame>12 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and Disability status measured by Oswestry Disability Index (ODI)</measure>
    <time_frame>12 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by EQ-5D</measure>
    <time_frame>12 or 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>complications of interest</measure>
    <time_frame>12 or 24 months</time_frame>
  </other_outcome>
  <enrollment type="Actual">76</enrollment>
  <condition>Subjects Received MAGNIFUSE in Posterolateral Lumbar Spine</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who underwent a posterolateral surgical procedure with MAGNIFUSE in the lumbar&#xD;
        spine.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject's medical record must contain the following for the subject to be included:&#xD;
&#xD;
          1. Posterolateral surgical procedure using MAGNlFUSE with local autograft and/or iliac&#xD;
             crest bone graft at one or two continuous lumbar levels from L1-S1.&#xD;
&#xD;
          2. Radiographs available for fusion assessment by clinician at 12 and/or 24 month&#xD;
             post-surgery visits.&#xD;
&#xD;
          3. Subject must be at least 18 years old at the time of index procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject data will be excluded from this study if the medical record indicates:&#xD;
&#xD;
          1. Additional surgical treatment adjacent to the initial lumbar levels treated per&#xD;
             Inclusion Criterion 1.&#xD;
&#xD;
          2. Infection at index level(s) at time of surgery.&#xD;
&#xD;
          3. Extant tumor (evident at any level), spinal metastasis, or spinal tumor at the time of&#xD;
             surgery.&#xD;
&#xD;
          4. Pregnant at time of surgery.&#xD;
&#xD;
          5. Surgery is due to trauma (e.g., motor vehicle accident or high impact fall).&#xD;
&#xD;
          6. Use of growth factors or growth peptide (BMP2, BMP7, or iFactor) in the index-level&#xD;
             fusion surgery.&#xD;
&#xD;
          7. Procedure is a revision surgery for previously failed fusion at the surgery index&#xD;
             level(s).&#xD;
&#xD;
          8. Subjects with body mass index &gt; 40 at the time of surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Midwest Ortho. Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

